Organization: MaRS Innovation

Pfizer Canada funds MaRS Innovation for health sciences research

Pfizer Canada has contributed $800,000 to MaRS Innovation to support new ideas or technologies in health sciences research in areas of therapeutics, diagnostic and treatment tools, and manufacturing technologies. The MaRS Innovation – Pfizer Translational Research Fund will be managed by MaRS Innovation. Priority projects are in cardiovascular disease, inflammation, immunology, rare diseases, vaccines, and…

Encycle raises $2.85 million in start-up funding

Encycle Therapeutics Inc has completed financing of $2.85 million to support development of its nacellin platform chemistry and advance its therapeutics pipeline. The investment in the Toronto-based firm — spun off from the Univ of Toronto in collaboration with MaRS Innovation — will allow it to build on its relationships with pharmaceutical companies and position…

ChipCare finalizes $5-million series A financing

ChipCare Corp has closed a $5-million series A financing to bring its handheld, blood-testing platform for HIV and other infectious and non-communicable diseases to market. Financing for the Univ of Toronto start-up was led by Puffin Partners LP, Dallas TX, and includes MaRS Innovation, Maple Leaf Angels, Winfield Venture Group, Epic Capital and US and…

ChipCare finalizes $5-million series A financing

ChipCare Corp has closed a $5-million series A financing to bring its handheld, blood-testing platform for HIV and other infectious and non-communicable diseases to market. Financing for the Univ of Toronto start-up was led by Puffin Partners LP, Dallas TX, and includes MaRS Innovation, Maple Leaf Angels, Winfield Venture Group, Epic Capital and US and…

AvidBiologics completes VC financing round

Toronto-based AvidBiologics Inc has closed a financing round to move its antibody-drug conjugate (ADC) technologies into clinical trials. The privately held firm — a 2011 spinout from YM BioSciences Inc — secured an unspecified amount of financing from Lumira Capital (lead), MaRS Investment Accelerator Fund, MaRS Innovation, Rosseau Asset Management and the company’s founding investors.…

Three CECRs receive $4 million from Merck Canada

Merck Canada is investing $4 million in three Centres of Excellence for Commercialization and Research (CECR) as part of a $100-million commitment it made in 2010 when it closed its Merck Frosst Centre for Therapeutic Research in a global restructuring (R$, July 19/10). The funding goes to the Institute for Research in Immunology and Cancer…

CECR and BL-NCE funding extensions announced

The Networks of Centres of Excellence (NCE) secretariat has released the results of its competition to determine which of the original recipients of its two industry-facing programs will receive extended funding. The competition awarded renewed funding for four of the original 11 Centres of Excellence for Commercialization and Research (CECR) and one of the four…

CQDM and Ontario partners launch funding program

The Quebec Consortium for Drug Discovery (CQDM) and three Ontario organizations are launching the Quebec/Ontario CQDM Funding Program to support collaborative research projects and develop new tools for biopharmaceutical research. The program is seen as the first tangible realization of the emerging Ontario-Quebec Life Sciences Corridor, which was announced last year and accelerated with two…

MaRS and J&J to support early-stage technologies

MaRS Innovation has teamed with Johnson & Johnson Corporate Office of Science and Technology to launch a co-managed and co-financed fund for early-stage development of Toronto-based life sciences technologies. Each party will commit a defined capital pool to support high-potential projects identified by a joint management committee. The objective is to take a technology to…

MaRS Innovation to commercialize two technologies

MaRS Innovation has announced its first two medical technologies for commercialization. MaRS Innovation — funded through the Centres of Excellence for Commercialization and Research program (R$, October 7/08) — is collaborating with the Samuel Lunenfeld Research Institute (SLRI) to commercialize an umbilical cord stem cell technology to initially treat diabetes and possible cardiovascular disease and…